|
1
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bareschino MA, Schettino C, Colantuoni G,
Rossi E, Rossi A, Maione P, Ciardiello F and Gridelli C: The role
of antiangiogenetic agents in the treatment of breast cancer. Curr
Med Chem. 18:5022–5032. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cook KM and Figg WD: Angiogenesis
inhibitors: Current strategies and future prospects. CA Cancer J
Clin. 60:222–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Danza K, Pilato B, Lacalamita R, Addati T,
Giotta F, Bruno A, Paradiso A and Tommasi S: Angiogenetic axis
angiopoietins/Tie2 and VEGF in familial breast cancer. Eur J Hum
Genet. 21:824–830. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Senger DR, Van de Water L, Brown LF, Nagy
JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM and Dvorak HF:
Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer
Metastasis Rev. 12:303–324. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gu Q, Wang D, Wang X, Peng R, Liu J, Jiang
T, Wang Z, Wang S and Deng H: Basic fibroblast growth factor
inhibits radiation-induced apoptosis of HUVECs. I. The PI3K/AKT
pathway and induction of phosphorylation of BAD. Radiat Res.
161:692–702. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gingis-Velitski S, Zetser A, Flugelman MY,
Vlodavsky I and Ilan N: Heparanase induces endothelial cell
migration via protein kinase B/Akt activation. J Biol Chem.
279:23536–23541. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gerber HP, McMurtrey A, Kowalski J, Yan M,
Keyt BA, Dixit V and Ferrara N: Vascular endothelial growth factor
regulates endothelial cell survival through the
phosphatidylinositol 3′-kinase/Akt signal transduction pathway.
Requirement for Flk-1/KDR activation. J Biol Chem. 273:30336–30343.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fagiani E and Christofori G: Angiopoietins
in angiogenesis. Cancer Lett. 328:18–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cao Y, Sonveaux P, Liu S, Zhao Y, Mi J,
Clary BM, Li CY, Kontos CD and Dewhirst MW: Systemic overexpression
of angiopoietin-2 promotes tumor microvessel regression and
inhibits angiogenesis and tumor growth. Cancer Res. 67:3835–3844.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thomas M and Augustin HG: The role of the
Angiopoietins in vascular morphogenesis. Angiogenesis. 12:125–137.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tait CR and Jones PF: Angiopoietins in
tumours: The angiogenic switch. J Pathol. 204:1–10. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thurston G and Daly C: The complex role of
angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold
Spring Harb Perspect Med. 2:a0065502012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bhadada SV, Goyal BR and Patel MM:
Angiogenic targets for potential disorders. Fundam Clin Pharmacol.
25:29–47. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hill SM and Blask DE: Effects of the
pineal hormone melatonin on the proliferation and morphological
characteristics of human breast cancer cells (MCF-7) in culture.
Cancer Res. 48:6121–6126. 1988.PubMed/NCBI
|
|
16
|
Cos S and Sánchez-Barceló EJ: Melatonin
and mammary pathological growth. Front Neuroendocrinol. 21:133–170.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Blask DE, Sauer LA and Dauchy RT:
Melatonin as a chronobiotic/anticancer agent: Cellular,
biochemical, and molecular mechanisms of action and their
implications for circadian-based cancer therapy. Curr Top Med Chem.
2:113–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reiter RJ: The pineal and its hormones in
the control of reproduction in mammals. Endocr Rev. 1:109–131.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Molis TM, Spriggs LL and Hill SM:
Modulation of estrogen receptor mRNA expression by melatonin in
MCF-7 human breast cancer cells. Mol Endocrinol. 8:1681–1690. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cos S, Blask DE, Lemus-Wilson A and Hill
AB: Effects of melatonin on the cell cycle kinetics and
‘estrogen-rescue’ of MCF-7 human breast cancer cells in culture. J
Pineal Res. 10:36–42. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Allegra M, Reiter RJ, Tan DX, Gentile C,
Tesoriere L and Livrea MA: The chemistry of melatonin's interaction
with reactive species. J Pineal Res. 34:1–10. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fraschini F, Demartini G, Esposti D and
Scaglione F: Melatonin involvement in immunity and cancer. Biol
Signals Recept. 7:61–72. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leon-Blanco MM, Guerrero JM, Reiter RJ,
Calvo JR and Pozo D: Melatonin inhibits telomerase activity in the
MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res.
35:204–211. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martínez-Campa CM, Alonso-González C,
Mediavilla MD, Cos S, González A and Sanchez-Barcelo EJ: Melatonin
down-regulates hTERT expression induced by either natural estrogens
(17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human
breast cancer cells. Cancer Lett. 268:272–277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blask DE, Dauchy RT, Sauer LA, Krause JA
and Brainard GC: Growth and fatty acid metabolism of human breast
cancer (MCF-7) xenografts in nude rats: Impact of constant
light-induced nocturnal melatonin suppression. Breast Cancer Res
Treat. 79:313–320. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Blask DE, Dauchy RT and Sauer LA: Putting
cancer to sleep at night: The neuroendocrine/circadian melatonin
signal. Endocrine. 27:179–188. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alvarez-García V, González A,
Martínez-Campa C, Alonso-González C and Cos S: Melatonin modulates
aromatase activity and expression in endothelial cells. Oncol Rep.
29:2058–2064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alvarez-García V, González A,
Alonso-González C, Martínez-Campa C and Cos S: Regulation of
vascular endothelial growth factor by melatonin in human breast
cancer cells. J Pineal Res. 54:373–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alvarez-García V, González A,
Alonso-González C, Martínez- Campa C and Cos S: Antiangiogenic
effects of melatonin in endothelial cell cultures. Microvasc Res.
87:25–33. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cos S, Alvarez-García V, González A,
Alonso-González C and Martínez-Campa C: Melatonin modulation of
crosstalk among malignant epithelial, endothelial and adipose cells
in breast cancer (Review). Oncol Lett. 8:487–492. 2014.PubMed/NCBI
|
|
31
|
Kajdaniuk D, Marek B, Kos-Kudła B,
Zwirska-Korczala K, Ostrowska Z, Buntner B and Szymszal J: Does the
negative correlation found in breast cancer patients between plasma
melatonin and insulin-like growth factor-I concentrations imply the
existence of an additional mechanism of oncostatic melatonin
influence involved in defense? Med Sci Monit. 8:CR457–CR461.
2002.PubMed/NCBI
|
|
32
|
Fandrey J and Genius J: Reactive oxygen
species as regulators of oxygen dependent gene expression. Adv Exp
Med Biol. 475:153–159. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lobov IB, Brooks PC and Lang RA:
Angiopoietin-2 displays VEGF-dependent modulation of capillary
structure and endothelial cell survival in vivo. Proc Natl Acad Sci
USA. 99:pp. 11205–11210. 2002; View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liang Y and Hyder SM: Proliferation of
endothelial and tumor epithelial cells by progestin-induced
vascular endothelial growth factor from human breast cancer cells:
Paracrine and autocrine effects. Endocrinology. 146:3632–3641.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Holash J, Wiegand SJ and Yancopoulos GD:
New model of tumor angiogenesis: Dynamic balance between vessel
regression and growth mediated by angiopoietins and VEGF. Oncogene.
18:5356–5362. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Currie MJ, Gunningham SP, Han C, Scott PA,
Robinson BA, Harris AL and Fox SB: Angiopoietin-1 is inversely
related to thymidine phosphorylase expression in human breast
cancer, indicating a role in vascular remodeling. Clin Cancer Res.
7:918–927. 2001.PubMed/NCBI
|
|
39
|
Sánchez-Barceló EJ, Cos S, Fernández R and
Mediavilla MD: Melatonin and mammary cancer: A short review. Endocr
Relat Cancer. 10:153–159. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cos S, González A, Martínez-Campa C,
Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ:
Estrogen-signaling pathway: A link between breast cancer and
melatonin oncostatic actions. Cancer Detect Prev. 30:118–128. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cos S, González A, Martínez-Campa C,
Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Melatonin
as a selective estrogen enzyme modulator. Curr Cancer Drug Targets.
8:691–702. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lissoni P, Rovelli F, Malugani F, Bucovec
R, Conti A and Maestroni GJ: Anti-angiogenic activity of melatonin
in advanced cancer patients. Neuro Endocrinol Lett. 22:45–47.
2001.PubMed/NCBI
|
|
43
|
Cui P, Luo Z, Zhang H, Su Y, Li A, Li H,
Zhang J, Yang Z and Xiu R: Effect and mechanism of melatonin's
action on the proliferation of human umbilical vein endothelial
cells. J Pineal Res. 41:358–362. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dai M, Cui P, Yu M, Han J, Li H and Xiu R:
Melatonin modulates the expression of VEGF and HIF-1α induced by
CoCl2 in cultured cancer cells. J Pineal Res. 44:121–126. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cos S, Martínez-Campa C, Mediavilla MD and
Sánchez-Barceló EJ: Melatonin modulates aromatase activity in MCF-7
human breast cancer cells. J Pineal Res. 38:136–142. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alvarez-García V, González A,
Alonso-González C, Martínez- Campa C and Cos S: Melatonin
interferes in the desmoplastic reaction in breast cancer by
regulating cytokine production. J Pineal Res. 52:282–290. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
González A, Alvarez-García V,
Martínez-Campa C, Alonso-González C and Cos S: Melatonin promotes
differentiation of 3T3-L1 fibroblasts. J Pineal Res. 52:12–20.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cui P, Yu M, Luo Z, Dai M, Han J, Xiu R
and Yang Z: Intracellular signaling pathways involved in cell
growth inhibition of human umbilical vein endothelial cells by
melatonin. J Pineal Res. 44:107–114. 2008.PubMed/NCBI
|
|
49
|
García-Santos G, Antolín I, Herrera F,
Martín V, Rodríguez-Blanco J, del Pilar Carrera M and Rodríguez C:
Melatonin induces apoptosis in human neuroblastoma cancer cells. J
Pineal Res. 41:130–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sainz RM, Mayo JC, Tan DX, León J,
Manchester L and Reiter RJ: Melatonin reduces prostate cancer cell
growth leading to neuroendocrine differentiation via a receptor and
PKA independent mechanism. Prostate. 63:29–43. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Longatti P, Perin A, Rizzo V, Comai S,
Giusti P and Costa CV: Ventricular cerebrospinal fluid melatonin
concentrations investigated with an endoscopic technique. J Pineal
Res. 42:113–118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Maestroni GJ and Conti A: Melatonin in
human breast cancer tissue: Association with nuclear grade and
estrogen receptor status. Lab Invest. 75:557–561. 1996.PubMed/NCBI
|
|
53
|
Hashimoto T, Wu Y, Boudreau N, Li J,
Matsumoto M and Young W: Regulation of tie2 expression by
angiopoietin - potential feedback system. Endothelium. 11:207–210.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ye F, Florian M, Magder SA and Hussain SN:
Regulation of angiopoietin and Tie-2 receptor expression in
non-reproductive tissues by estrogen. Steroids. 67:305–310. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Harfouche R, Echavarria R, Rabbani SA,
Arakelian A, Hussein MA and Hussain SN: Estradiol-dependent
regulation of angiopoietin expression in breast cancer cells. J
Steroid Biochem Mol Biol. 123:17–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Holopainen T, Saharinen P, D'Amico G,
Lampinen A, Eklund L, Sormunen R, Anisimov A, Zarkada G, Lohela M,
Heloterä H, et al: Effects of angiopoietin-2-blocking antibody on
endothelial cell-cell junctions and lung metastasis. J Natl Cancer
Inst. 104:461–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew
J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, et
al: A human monoclonal anti-ANG2 antibody leads to broad antitumor
activity in combination with VEGF inhibitors and chemotherapy
agents in preclinical models. Mol Cancer Ther. 9:145–156. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hashizume H, Falcón BL, Kuroda T, Baluk P,
Coxon A, Yu D, Bready JV, Oliner JD and McDonald DM: Complementary
actions of inhibitors of angiopoietin-2 and VEGF on tumor
angiogenesis and growth. Cancer Res. 70:2213–2223. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Leow CC, Coffman K, Inigo I, Breen S,
Czapiga M, Soukharev S, Gingles N, Peterson N, Fazenbaker C, Woods
R, et al: MEDI3617, a human anti-Angiopoietin 2 monoclonal
antibody, inhibits angiogenesis and tumor growth in human tumor
xenograft models. Int J Oncol. 40:1321–1330. 2012.PubMed/NCBI
|
|
60
|
Mazzieri R, Pucci F, Moi D, Zonari E,
Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, et
al: Targeting the ANG2/TIE2 axis inhibits tumor growth and
metastasis by impairing angiogenesis and disabling rebounds of
proangiogenic myeloid cells. Cancer Cell. 19:512–526. 2011.
View Article : Google Scholar : PubMed/NCBI
|
